VENCLEXTA is a prescription medicine used in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with
newly diagnosed AML who are 75 years of age or older, or have other medical conditions that prevent the use of standard chemotherapy. It is not known if VENCLEXTA is safe and effective in children.

VENCLEXTA + azacitidine

PROVEN TO HELP
SOME ADULTS WITH
NEWLY DIAGNOSED
AML LIVE LONGER

Half of patients treated with VENCLEXTA + azacitidine were still alive at 15 months vs 10 months for those receiving treatment with azacitidine alone.

In a clinical study of 431 adults with newly diagnosed acute myeloid leukemia (AML), who are 75 years of age or older, or have other medical conditions that prevent the use of standard chemotherapy, 286 patients received VENCLEXTA + azacitidine and 145 patients received azacitidine + placebo (an inactive medication), also considered as azacitidine alone.

It is not known if VENCLEXTA is safe and effective in children.

Actor portrayal.

VENCLEXTA + azacitidine

PROVEN TO HELP
SOME ADULTS WITH
NEWLY DIAGNOSED
AML LIVE LONGER

Half of patients treated with VENCLEXTA + azacitidine were still alive at 15 months vs 10 months for those receiving treatment with azacitidine alone.

In a clinical study of 431 adults with newly diagnosed acute myeloid leukemia (AML), who are 75 years of age or older, or have other medical conditions that prevent the use of standard chemotherapy, 286 patients received VENCLEXTA + azacitidine and 145 patients received azacitidine + placebo (an inactive medication), also considered as azacitidine alone.

It is not known if VENCLEXTA is safe and effective in children.

Actor portrayal.